Increased clinical benefit of atorvastatin at high doses in stable coronary heart disease
This article has no abstract so we have provided the first paragraph of the full text.
Current guidelines recommend using lipid-lowering therapy to achieve an LDL cholesterol level below 1.8 mmol/l in patients with acute coronary syndromes, but reduction below 2.6 mmol/l is not proven to provide additional clinical benefit in patients with stable coronary heart disease (CHD). A recently published report from the Treating to New Targets (TNT) study examines the effect of high-dose atorvastatin on cardiovascular events in this population.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mal-function of TLRs by SOCSNature Immunology News and Views (01 Feb 2006)
Solar size variationNature News and Views (31 Jul 1980)
